Cell and gene therapies are yielding new treatments for genetic disorders including cancers and inherited diseases.
Single-cell DNA sequencing on the Tapestri Platform provides the most sensitive and nuanced quantification of genetic edits made to single cells with a simple one-day high-throughput workflow. Quantification of on- and predicted off-target edits for multiple targets, zygosity, and translocations are all measured simultaneously from a single assay for up to 10,000 single cells per sample.
After making genomic edits, single-cell sequencing garners richer information than bulk assays, resulting in accurate quantification of all genome editing cell outcomes without the need for multiple cumbersome assays and cell culture.
The Tapestri Platform integrates with cell and gene therapy workflows during development as well as during final product testing and release in manufacturing. Having faster turnaround and more complete data at these steps will aid in reducing the time and cost for cell and gene therapies to go to market.
Offered Free by: MissionBio
See All Resources from: MissionBio